UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 9/2011, Volume 66, Issue 9, pp. 2107 - 2111
HIV/AIDS | Older patients | Drug-drug interactions | Polypharmacy | Cardiovascular drugs | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Central Nervous System Agents - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Hormones - therapeutic use | Methadone - therapeutic use | Male | Narcotics - therapeutic use | Hormones - adverse effects | Central Nervous System Agents - adverse effects | Narcotics - adverse effects | Socioeconomic Factors | Drug Interactions | Adult | Anti-HIV Agents - therapeutic use | Female | Substance Abuse, Intravenous - complications | Anti-HIV Agents - adverse effects | HIV Infections - virology | Substance-Related Disorders - complications | Cardiovascular Agents - therapeutic use | Drug Prescriptions - statistics & numerical data | Aging - physiology | Switzerland - epidemiology | Gastrointestinal Agents - therapeutic use | HIV Infections - complications | HIV Infections - drug therapy | Aged | Gastrointestinal Agents - adverse effects | Methadone - adverse effects | Cardiovascular Agents - adverse effects | Cohort Studies | Antiretroviral drugs | Comparative analysis | Human immunodeficiency virus--HIV | Risk assessment | Index Medicus
Journal Article
CNS drugs, ISSN 1172-7047, 2010, Volume 24, Issue 8, pp. 655 - 667
Pyrazinamide, adverse reactions | Aminoglycosides, adverse reactions | Ethambutol, adverse reactions | Antituberculars, adverse reactions | Adverse-drug-reactions | Isoniazid, adverse reactions | Cycloserine, adverse reactions | Metronidazole, adverse reactions | Tuberculosis | Aminosalicylic-acid, adverse reactions | Ethionamide, adverse reactions | Thioacetazone, adverse reactions | Linezolid, adverse reactions | Meropenem, adverse reactions | Rifampicin, adverse reactions | Fluoroquinolones, adverse reactions | Capreomycin, adverse reactions | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Antitubercular Agents - adverse effects | Humans | Antitubercular Agents - pharmacology | Male | Animals | Mycobacterium tuberculosis | Tuberculosis - drug therapy | Central Nervous System - drug effects | Female | Nervous System Diseases - chemically induced | Antitubercular Agents - poisoning | Antitubercular Agents - therapeutic use | Peripheral Nervous System - drug effects | Index Medicus
Journal Article
CNS drugs, ISSN 1172-7047, 2008, Volume 22, Issue 3, pp. 213 - 237
Clonidine, adverse reactions | Attention deficit hyperactivity disorder, treatment | Atomoxetine, adverse reactions | Central nervous system stimulants, adverse reactions | Bupropion, adverse reactions | Alpha 2 adrenergic receptor agonists, adverse reactions | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Growth Disorders - chemically induced | Mental Disorders - epidemiology | Mental Disorders - chemically induced | Cardiovascular Diseases - prevention & control | Humans | Growth Disorders - prevention & control | Mental Disorders - prevention & control | Clinical Trials as Topic | Attention Deficit Disorder with Hyperactivity - drug therapy | Antidepressive Agents - therapeutic use | Nervous System Diseases - epidemiology | Nervous System Diseases - prevention & control | Central Nervous System Stimulants - therapeutic use | Propylamines - therapeutic use | Central Nervous System Stimulants - adverse effects | Atomoxetine Hydrochloride | Growth Disorders - epidemiology | Cardiovascular Diseases - epidemiology | Nervous System Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Antidepressive Agents - adverse effects | Propylamines - adverse effects | Anorexia | Hyperactivity | Complications | Attention deficit hyperactivity disorder | Clinical trials | FDA approval | Epidemiology | Cancer therapies | Carcinogenesis | Children & youth | Prescription drugs | Sleep disorders | Side effects | Stimulants | Insomnia | Cell cycle | Teenagers | Drug dosages | Seizures | Child & adolescent psychiatry | Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Mitosis | Humans | Middle Aged | Male | Electric Stimulation Therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Glioblastoma - surgery | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Dacarbazine - analogs & derivatives | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Temozolomide | Antineoplastic Agents, Alkylating - adverse effects | Glioblastoma - drug therapy | Statistical analysis | Toxicity | Glioblastoma | Central nervous system | Clinical trials | Cell division | Nervous system | Maintenance | Patients | Survival | Chemotherapy | Scalp | Skin | Portable equipment | Electric fields | Tumors
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 05/2017, Volume 77, Issue 8, pp. 859 - 883
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Anti-Infective Agents - metabolism | Anti-Infective Agents - pharmacology | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Gastrointestinal Agents - administration & dosage | Antineoplastic Agents - administration & dosage | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Central Nervous System Agents - adverse effects | Antineoplastic Agents - metabolism | Drug Interactions | Antineoplastic Agents - adverse effects | Antineoplastic Agents - pharmacology | Cell Line | Anti-Infective Agents - adverse effects | Immunologic Factors - administration & dosage | Gastrointestinal Agents - pharmacology | Anti-Infective Agents - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP3A - metabolism | Central Nervous System Agents - administration & dosage | Central Nervous System Agents - pharmacology | Central Nervous System Agents - metabolism | Gastrointestinal Agents - adverse effects | Immunologic Factors - adverse effects | Immunologic Factors - metabolism | Immunologic Factors - pharmacology | Gastrointestinal Agents - metabolism | Cytochrome | Health care | Drugs | Enzymes | Membranes | Excretion | Decision making | Organs | Substrate inhibition | Breast cancer | Glycoproteins | Metabolism | Substrates | Proteins | Side effects | Blood-brain barrier | Plasma membranes | Protein expression | Protein transport | P-Glycoprotein | Transporter | Inducers
Journal Article
2011, 12th ed., McGraw-Hill's AccessMedicine, ISBN 0071624422, 2047
eBook